Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab
✍ Scribed by T. Bongartz; P. Härle; S. Friedrich; S. Karrer; T. Vogt; A. Seitz; U. Müller-Ladner
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 147 KB
- Volume
- 52
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Psoriatic onycho‐pachydermo periostitis (POPP) is recognized as a rare subset of psoriatic arthritis, characterized by psoriatic onychodystrophy, connective tissue thickening above the distal phalanx, and a periosteal reaction. Therapy for this rare disease is based on treatments used for psoriatic arthritis, but traditional disease‐modifying antirheumatic drugs, such as sulfasalazine and methotrexate, have shown inconsistent and unsatisfactory results. We report herein a successful therapeutic approach for POPP using the fully human anti–tumor necrosis factor (TNF) antibody adalimumab in a 42‐year‐old male patient. After 4 months of anti‐TNF treatment, a remarkable normalization of the clinical appearance was achieved and magnetic resonance imaging showed complete resolution of the initial inflammatory lesions. Therefore, we consider a TNF‐blocking strategy as promising for treatment of POPP.